CBD has received regulatory approval in the US, Europe, and India for three forms of drug-resistant childhood epilepsy, with evidence showing reduced seizure frequency and generally favorable safety.
pediatric neurologists, parents of children with drug-resistant epilepsy, healthcare policymakers
What the researchers found
CBD has been approved for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex in multiple countries. Clinical trials and observational studies show it can lower seizure frequency and improve quality of life. Common adverse events include somnolence, diarrhea, and gastrointestinal issues. Cost remains a barrier, especially in low- and middle-income countries.
Why it matters
Drug-resistant epilepsy affects children who do not respond to conventional anti-seizure medications. CBD represents one of the few new treatment options to receive regulatory approval across multiple jurisdictions for these severe conditions.
The numbers in context
Approved for 3 conditions: Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex. Regulatory approval in US, Europe, and India. Common adverse events: somnolence, diarrhea, GI issues. Cost is a significant barrier in LMICs.
How the study worked
Narrative review of CBD's pharmacological properties, mechanisms of action, and clinical evidence from trials and observational studies for pediatric drug-resistant epilepsy, including regulatory landscape discussion.
What this study cannot tell us
Narrative review without systematic methodology. Does not quantify seizure reduction across all studies. Limited discussion of long-term outcomes. Cost-effectiveness analysis not included.
How to read the evidence
Multiple regulatory approvals based on clinical trial data across three conditions places this at strong evidence, despite the review's narrative format.
When this study was published
Reviews current evidence and regulatory status.
The bigger picture
CBD's journey from cannabis compound to approved pharmaceutical represents a rare success in cannabinoid medicine. However, access barriers due to cost and regulatory complexity mean many children who could benefit still cannot access treatment.
Questions still open
- Can lower-cost CBD formulations achieve similar efficacy?
- What are the long-term developmental outcomes for children on CBD treatment?
Common questions
Which types of epilepsy can CBD treat?
Is CBD safe for children with epilepsy?
Read the original research
Update on Cannabidiol in Drug-Resistant Epilepsy.
Indian journal of pediatrics, 92(1), 61-69
Citation
Singh, Akanksha; Madaan, Priyanka; Bansal, Dipika. (2025). Update on Cannabidiol in Drug-Resistant Epilepsy.. Indian journal of pediatrics, 92(1), 61-69. https://doi.org/10.1007/s12098-024-05337-1
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk